Onesource Specialty Pharma profit and loss

Latest FY26

Revenue: ₹1,422cr−1.6% on FY25
EBITDA: ₹304cr−34.8% on FY25
Net profit: −₹73.8cr−₹18.0 cr in FY25
EPS: −₹6.44−₹1.63 in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025

Expenses
	1,684	1,422	1,445
	11.5	15.0	17.5
	1,695	1,437	1,462
	526	437	328
	0.0	0.0	30.1
	4.7	7.9	76.7
	273	242	215
	126	122	166
	288	279	274
	484	430	328
	1,702	1,519	1,419
	396	304	467
	108	25.1	193
Profit
	−7.0	−82.0	43.8
	−13.1	−9.9	−111
	−20.1	−92.0	−67.1
	1.7	2.2	11.8
	−20.2	−20.4	−61.6
	−18.5	−18.2	−49.8
	−1.6	−73.8	−18.0
	−1.6	−73.8	−17.3
	0.0	0.0	−0.7
	14.0	16.1	−3.2
	12.4	−57.7	−21.1
	—	−73.8	—
Per share
	−₹0.15	−₹6.44	−₹1.63
	−₹0.15	−₹6.44	−₹1.63
Continuing & discontinued operations
	0.0	0.0	−0.7
Other comprehensive income — detail
	14.0	16.1	−3.2
	−5.4	−6.7	—
	0.0	0.0	3.2
	19.4	22.7	—
	—	−57.7	—
Per share — as-filed variants
	−₹0.15	−₹6.44	−₹1.63
	−₹0.15	−₹6.44	−₹1.63
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,153	977	1,010
	68.5%	68.7%	69.9%
Adjusted (ex-exceptional items) — derived
	−7.0	−82.0	43.8
	−13.1	−9.9	−111
	3.6	−65.8	26.4
	₹0.34	−₹5.74	₹2.39

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ONESOURCE₹1,569.60

Onesource Specialty Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSTAR DIVISLAB GLAND PFIZER POLYMED RAINBOW KIMS JUBLPHARMAMcap ₹17,991 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	1,444.9	1,421.6	1,683.8
Other Income	17.5	15.0	11.5
Total Income	1,462.3	1,436.6	1,695.3
Expenses
+ Cost of Materials Consumed	328.2	436.8	525.7
+ Purchases of Stock-in-Trade	30.1	0.0	0.0
+ Changes in Inventories	76.7	7.9	4.7
+ Employee Benefit Expense	215.3	242.3	273.2
+ Finance Costs	166.3	122.2	126.1
+ Depreciation & Amortisation	273.9	279.1	288.3
+ Other Expenses	328.0	430.5	484.4
Total Expenses	1,418.5	1,518.6	1,702.3
EBITDA	466.5	304.2	395.9
EBIT	192.6	25.1	107.6
Profit
PBT before Exceptional Items	43.8	-82.0	-7.0
+ Exceptional Items	-110.8	-9.9	-13.1
Pretax Income	-67.1	-92.0	-20.1
+ Current Tax	11.8	2.2	1.7
+ Deferred Tax	-61.6	-20.4	-20.2
Tax Expense	-49.8	-18.2	-18.5
Net Income	-18.0	-73.8	-1.6
+ Net Income — Continuing Ops	-17.3	-73.8	-1.6
+ Net Income — Discontinued Ops	-0.7	0.0	0.0
+ Other Comprehensive Income	-3.2	16.1	14.0
Total Comprehensive Income	-21.1	-57.7	12.4
Net Income to Common	—	-73.8	—
Per Share
Basic EPS	-1.63	-6.44	-0.15
Diluted EPS	-1.63	-6.44	-0.15
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	-0.7	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	-3.2	16.1	14.0
+ Items NOT to be Reclassified to P&L	—	-6.7	-5.4
+ Tax on Items NOT to be Reclassified	3.2	0.0	0.0
+ Items to be Reclassified to P&L	—	22.7	19.4
Comprehensive Income — Owners of Parent	—	-57.7	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	-1.63	-6.44	-0.15
Diluted EPS — Continuing Operations	-1.63	-6.44	-0.15
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,009.8	976.9	1,153.4
Gross Margin %	69.89	68.72	68.50
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	43.8	-82.0	-7.0
− Exceptional Items (reconciliation)	-110.8	-9.9	-13.1
Net Income Adj (tax-effected)	26.4	-65.8	3.6
EPS Adj	2.39	-5.74	0.34
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00
Filed Debt Equity	0.16	—	—
Filed Dscr	0.63	—	—
Filed Iscr	1.52	—	—
Paid Up Equity Capital	11.4	11.5	11.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.